Skip to main content
. 2022 Jun 15;23(12):6689. doi: 10.3390/ijms23126689

Figure 3.

Figure 3

(A,B) Galunisertib increases the rate of artificial wound closure. Representative serial images of in vitro scratch assays from 0–24 h (A) show that galunisertib (10 µM) significantly increased the rate of in vitro wound closure of FDPFs compared to untreated FPDFs (B). Data are presented as mean percent open wound ± SEM (* p < 0.05).